Focus On , Pharmacology

Grapiprant for Control of Osteoarthritis Pain in Dogs

Dawn Merton Boothe DVM, MS, PhD, DACVIM, DACVCP

Dr. Boothe received her DVM degree from Texas A&M in 1980, completed a small animal internship at Auburn University in 1980, received an MS degree from Texas A&M in 1985, completed a residency in small animal medicine in 1985, completed a PhrMA Fellowship in 1989, and received a PhD degree in 1989. In 1990, she joined Texas A&M in the Department of Veterinary Physiology & Pharmacology and became a professor. In 2003, she joined the Departments of Anatomy, Physiology and Pharmacology and Clinical Sciences at Auburn in 2003, where she directs the Clinical Pharmacology Laboratory. Dr. Boothe has authored or coauthored approximately 125 peer-reviewed scientific publications, 60 book chapters, and 2 textbooks. She received the Texas A&M University Achievement Award in Teaching, the Jack Mara Scientific Achievement Award for contributions in clinical pharmacology of the critical care patient, Auburn University Outstanding Graduate Student Mentor Award, the Zoetis Award for Excellence in Research, and an Alumni Professorship.

Grapiprant for Control of Osteoarthritis Pain in Dogs
FEEL NO PAIN? Grapiprant is a nonsteroidal anti-inflammatory drug that helps dogs suffering from the pain caused by osteoarthritis. Photo: Goodman

For centuries, nonsteroidal anti-inflammatory drugs (NSAIDs) have been used for pain control. However, their use has been associated with potentially life-threatening adverse drug events. Grapiprant is a novel drug for treatment of osteoarthritic pain in dogs. Approved in 2016, it is a non-cyclooxygenase (COX)-inhibiting NSAID. Grapiprant is a highly selective, potent inhibitor of the prostaglandin (PG) E₂ EP₄ receptor, which is primarily responsible for the pain and inflammation associated with osteoarthritis.1 Grapiprant works downstream of traditional NSAIDs in the arachidonic acid cascade. A review of the arachidonic acid cascade and its role in inflammation can be found in a recent review.2

In the United States, grapiprant has been approved for treatment of osteoarthritis in dogs. However, because it has only been 3 years since drug approval, nonbiased controlled clinical trials have not yet compared its safety or efficacy with that of other NSAIDs. Although grapiprant has not been on the market long enough for clinical trials and adverse events to be effectively assessed, this report reviews the existing literature about its safety or efficacy, especially information about its use in dogs with osteoarthritis. Grapiprant is not approved for use in cats.


Grapiprant belongs to the piprant class of drugs, which are prostaglandin receptor antagonists; grapiprant selectively targets EP₄.1,3 However, despite this selectivity, because of the diverse locations of EP₄ receptors and physiological responses to prostaglandin mediated by EP₄, grapiprant has the potential to influence multiple actions of PGE₂. For example, PGE₂/EP₄ homeostatic interactions include gastrointestinal, hemostatic, renal, and immune regulation.4 Other functions include wound healing, bone metabolism, and skin immunity.5,6 Although its primary ligand is PGE₂, EP₄ also binds to PGF₂α and PGE₁, but it is not clear whether physiologic responses to these ligands are blocked by grapiprant.7

Because grapiprant’s antagonism of the EP₄ receptor seems to be selective, its effects at other sites are minimized.1,3,8 The magnitude of effect increases with plasma concentration. Binding is competitive, suggesting that efficacy is time-dependent, further suggesting that the dosing interval be based on elimination.5 According to in vitro studies of receptors in dogs and rodent and human pain models, the minimum plasma drug concentration for efficacious analgesia in dogs is 114 to 164 ng/mL.8 The dose needed to achieve this concentration, based on pharmacokinetic studies in dogs, is 2 mg/kg.8 However, according to Freedom of Information laws in Europe, the dose justification has not been fully supported and more than one dose a day may be necessary.9


Several studies have described the disposition of grapiprant in dogs.8,10,11 Key pharmacokinetic parameters covered here are oral bioavailability, tissue distribution, and elimination.

Oral Bioavailability

Oral disposition presents some factors that influence bioavailability. In female Labrador retrievers, grapiprant given as a pure powder in a capsule was approximately 100% orally bioavailable when given to fasted animals, but only 60% bioavailable when given to fed animals.10 Furthermore, the time to peak plasma concentration was prolonged from 1 (fasted) to 3 hours, and the peak plasma concentration was reduced by approximately 40% when animals were fed. Study findings that plasma concentrations remained above the presumed minimum effective concentration (164 ng/mL) for approximately 6 hours regardless of feeding suggest that the drug can be given with food10; however, efficacy might be affected and clients should be consistent as to how they administer the drug. Oral bioavailability is also affected by formulation, being 40% to 60% higher when given as the approved tablet rather than as a suspension.11 As such, manipulation of the approved formulation, including use of compounded grapiprant, should be avoided. If the tablet is scored (e.g., 20 and 60 mg), the dose can be calculated in half-tablet increments. If not scored (e.g., 100 mg), equal distribution of drug cannot be assumed and equal dosing may not occur with each drug half. No evidence could be found to address efficacy of crushed tablets.

In fasted beagles, oral bioavailability increased disproportionately more than dose, suggesting saturation of drug-metabolizing enzymes or transporters.8 Another study demonstrated an increase of 20- to 25-fold in maximum serum concentration and area under the curve in 4 beagles receiving 6 or 50 mg/kg.11 As such, care should be taken to avoid overdosing, and extra caution may be indicated for patients when hepatic function is of concern.

Tissue Distribution

As with other NSAIDs, grapiprant is highly (about 95%) bound to plasma proteins,5 and its displacement can increase unbound, pharmacologically active drug. However, clearance is likely to increase for the unbound drug. Nonetheless, caution may be indicated when using grapiprant with other highly protein-bound drugs (e.g., cefovecin, doxycycline), particularly if hepatic function is impaired. High binding to proteins at the site of inflammation may prolong efficacy beyond that predicted by its half-life.


Grapiprant is cleared primarily via cytochrome-mediated (CYP450) hepatic metabolism, although the specific enzymes have not been identified. Differences in CYP450 metabolism are increasingly being identified as a possible cause of adverse drug events among dogs of different breeds.12 Furthermore, for other NSAIDs, polymorphisms resulting in different rates of hepatic metabolism (poor to ultra-efficient metabolizers) have been identified in dogs.13 Grapiprant metabolites are excreted in bile, urine, and feces, but neither the extent of metabolism nor enterohepatic circulation have been reported. An elimination half-life of approximately 5 hours indicates that the drug will not significantly accumulate in healthy dogs after 24-hour dosing.11 After grapiprant administration is discontinued, most of the drug will be eliminated within 24 hours. Indeed, during a 24-hour dosing interval, approximately 90% of the drug will be eliminated within 15 hours, leaving a substantive drug-free period for organs of elimination, which may facilitate safety. Efficacy may be affected, although binding of NSAIDs to inflammatory proteins at the site of action has been demonstrated to contribute to a longer than expected duration of effect, based on elimination half-life.14,15

Safety of grapiprant in dogs that weigh less than 3.6 kg or are younger than 9 months has not been established. As with all NSAIDs, the lowest minimum effective dose should be established for each patient. A duration of administration has not been stipulated.

An elimination half-life of approximately 5 hours indicates that the drug will not significantly accumulate in healthy dogs after 24-hour dosing.11


Evidence of grapiprant’s efficacy is largely limited to field trials implemented during the approval process. All clinical trials were based on a placebo rather than a positive control (NSAID). In 1 trial, 262 dogs (131 per treatment group) with osteoarthritis, ranging from 2 to 17 years of age and weighing 4 to 60 kg, received either placebo or grapiprant at the labeled dose of 2 mg/kg PO q24h for 28 days.16 Evidence of efficacy was based on client-completed Canine Brief Pain Inventory responses and was considered successful for 48% of dogs receiving grapiprant and only 31% receiving placebo. However, the implication of this narrow efficacy difference (17%) warrants further consideration. According to the U.S. Food and Drug Administration (FDA) adverse event reporting site (, the fourth most common adverse event recorded for grapiprant was lack of efficacy, yet this effect was noted in only 1.4% of dogs receiving the comparison drug, deracoxib (Table 1). These data indicate a need for head-to-head randomized controlled clinical trials comparing grapiprant efficacy with that of other NSAIDs.


The potential safety of grapiprant is supported by 3 sources: animal safety studies, field trials implemented during the approval process (as reported in the Freedom of Information Act and the product package insert), and postmarket surveillance.

Animal Safety Studies

Among 8 beagles receiving 1 or 50 mg/kg grapiprant PO q24h for 9 months (4 dogs/group), no serious clinical-pathologic adverse drug events were noted. Although total serum protein and albumin concentrations decreased significantly compared with those of controls, all remained within normal limits.17 Indicators of hemostasis did not change. A second study, also among beagles, demonstrated that grapiprant at 6 or 50 mg/kg/day for 15 days was well tolerated.11 In contrast, studies of deracoxib cited in the  product package insert revealed abnormalities consistent with altered renal function in dogs receiving 5 times the recommended dose for 6 months, as well as vomiting, melena, and gastrointestinal lesions in dogs receiving 5 to 50 times the recommended dose for 14 days.

Field Trials

Data from a grapiprant clinical trial involving client-owned dogs with osteoarthritis receiving either placebo (n=131) or grapiprant (n=131) at 2 mg/kg daily for 28 days indicated a higher incidence of adverse drug events in the grapiprant group. However, these events were not serious; the most common were vomiting (24% with grapiprant versus 9% with placebo), diarrhea or soft stool (17% versus 13%), anorexia (9% versus 7%), and lethargy (6% versus 2%).16 Similarly, according to the product package insert, among 366 client-owned dogs given 2 or 5 mg/kg q24h or 4 mg/kg q12h, the most common adverse events were intermittent diarrhea, vomiting, and anorexia. Serum alkaline phosphatase and alanine aminotransferase increased and total protein decreased with dose, but the dogs remained clinically normal.

Postmarket Surveillance

A third source of adverse drug event data is the FDA adverse event reporting site. The proportion of the most common adverse events (the number of times the event was reported divided by the total number of reports for that drug) was determined for grapiprant and then compared with the same events reported for deracoxib (Table 1). Of the approximately 2300 reports for grapiprant, the most common adverse events were diarrhea (31%) and vomiting (22%). The incidence of serious adverse events was consistently (numerically) lower than that for deracoxib. However, these data do not account for differences in the number of dogs in the United States who received either drug.

Grapiprant is a sulfa drug, as are many NSAIDs approved for use in dogs, but unlike sulfonamide antimicrobials, grapiprant does not contain an arylamine. As such, although allergies typical of sulfonamide antimicrobials are unlikely, adverse events associated with sulfa components may occur. Pork liver is added as a flavoring agent, which could potentially contribute to food allergies.

It is important to remember that even if grapiprant targets only EP₄ receptors, these receptors play roles at several other body sites. Thus, grapiprant use may lead to other adverse events.

Grapiprant is a sulfa drug, as are many NSAIDs approved for use in dogs, but unlike sulfonamide antimicrobials, grapiprant does not contain an arylamine.


Two common pathways in drug, diet, or supplement interactions involve efflux transport proteins such as P-glycoprotein (MDR-1, ABCB-1) and CYP450 drug-metabolizing enzymes. According to the product package insert, grapiprant is a substrate for P-glycoprotein, which is present at portals of entry and tissue sanctuaries. As such, extra attention might be given to possible adverse drug events in breeds deficient in P-glycoprotein or if grapiprant is given with other medications known or suspected to interact with P-glycoprotein (e.g., cyclosporine, rifampin, imidazole antifungal drugs [ketoconazole, itraconazole, fluconazole]).17

The specific CYP450 enzymes responsible for metabolizing grapiprant have not been reported. However, the effects of other drugs that are broad inducers (e.g., phenobarbital, rifampin) or inhibitors (e.g., cyclosporine, chloramphenicol, imidazole antifungal drugs) of CYP450 enzymes18 mandate extra attention to potential adverse drug events if used with grapiprant. Grapiprant does not seem to alter the metabolism of other drugs, including itself: the product package insert indicates that in dogs, grapiprant is not an inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Furthermore, in beagles receiving either 6 or 50 mg/kg, grapiprant did not accumulate in plasma despite a 28-day treatment period.8 As such, grapiprant probably can be safely combined with a variety of other drugs; however, more studies are needed.


Overall, grapiprant may be useful for dogs with osteoarthritis. However, its relative efficacy compared with other NSAIDs has not yet been demonstrated.

  • Pharmacodynamics: Grapiprant antagonizes EP₄ (highly selectively).
  • Pharmacokinetics: Oral bioavailability is negatively affected by food and potentially by manipulation of the formulation; clearance decreases in a dose-dependent fashion.
  • Efficacy: Research findings may suggest that the efficacy of grapiprant is less than that of other NSAIDs.
  • Safety: Safety of grapiprant may be superior to NSAIDs but direct comparison studies are needed.
  • Adverse events: Although grapiprant can lead to adverse events typical of NSAIDs, more serious adverse events are not common.
  • Drug interactions: Drug interactions seem to be minimal, suggesting that grapiprant can be combined safely with most classes of non-NSAID analgesic drugs. Nonetheless, because the drug has been approved for only a short time, given that the EP₄ receptor plays a major role in the normal physiology of multiple organs (including the gastrointestinal tract and kidneys) and hemostasis, caution is recommended with its use, particularly in the presence of comorbidities.

More studies are needed to demonstrate the breadth of grapiprant’s analgesic efficacy and to compare its safety with that of COX-2–targeting NSAIDs. To facilitate the generation of safety evidence, report adverse events (including therapeutic failure) to the manufacturer or FDA (


1. Shaw KK, Rausch-Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci 2015;2(1):3-9.

2. Hanna VS, Hafez EAA. Synopsis of arachidonic acid metabolism: a review. J Adv Res 2018;11:23-32.

3. Chandrasekhar S, Yu XP, Harvey AK, et al. Analgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists. Pharmacol Res Perspect 2017;5(3):e00316.

4. Yokoyama U, Iwatsubo K. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 2013;65(3):1010-1052.

5. Markovič T, Jakopin Ž. Structural features of subtype-selective EP receptor modulators. Drug Discov Today 2017;22(1):57-71.

6. Hosono K, Isonaka R. Signaling of prostaglandin E receptors, EP3 and EP4 facilitates wound healing and lymphangiogenesis with enhanced recruitment of M2 macrophages in mice. PLoS One 2016;11(10):e0162532.

7. Kiriyama M, Ushikubi F. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997;122(2):217–224.

8. Nagahisa A, Okumura T. Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. J Vet Pharmacol Ther 2017;40(3):285-292.

9. European Medicines Agency. CVMP assessment report for Galliprant. Accessed July 2019.

10. Łebkowska-Wieruszewska B, Barsotti G, Lisowski A, et al. Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. N Z Vet J 2017;65(1):19-23.

11. Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmacol Ther 2016;39(6):566-571.

12. Campion DP, Dowell FJ. Translating pharmacogenetics and pharmacogenomics to the clinic: progress in human and veterinary medicine. Front Vet Sci 2019;6:22.

13. Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 2001;297(2):638-645.

14. Lees P, Landoni MF, Giraudel J, Toutain PL. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 2004;27(6):479-490.

15. De Vito V, Salvadori M. Pharmacokinetic/pharmacodynamic evaluation of grapiprant in a carrageenan-induced inflammatory pain model in the rabbit. J Vet Pharmacol Ther 2017;40(5):468-475.

16. Rausch-Derra L, Huebner M. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis.
J Vet Intern Med 2016;30(3):756-763.

17. Martinez M, Modric S, Sharkey M, et al. The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther 2008;31(4):285-300.

18. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35(5):361-390. Protection Status
[gravityform id="6" title="false" description="false"]
<div class='gf_browser_unknown gform_wrapper' id='gform_wrapper_6' style='display:none'><form method='post' enctype='multipart/form-data' id='gform_6' action='/grapiprant-for-control-of-osteoarthritis-pain-in-dogs/'> <div class='gform_body'><ul id='gform_fields_6' class='gform_fields top_label form_sublabel_below description_below'><li id='field_6_1' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label gfield_label_before_complex' >Name<span class='gfield_required'>*</span></label><div class='ginput_complex ginput_container no_prefix has_first_name no_middle_name has_last_name no_suffix gf_name_has_2 ginput_container_name' id='input_6_1'> <span id='input_6_1_3_container' class='name_first' > <input type='text' name='input_1.3' id='input_6_1_3' value='' aria-label='First name' aria-required="true" aria-invalid="false" /> <label for='input_6_1_3' >First</label> </span> <span id='input_6_1_6_container' class='name_last' > <input type='text' name='input_1.6' id='input_6_1_6' value='' aria-label='Last name' aria-required="true" aria-invalid="false" /> <label for='input_6_1_6' >Last</label> </span> </div></li><li id='field_6_2' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label' for='input_6_2' >Email<span class='gfield_required'>*</span></label><div class='ginput_container ginput_container_email'> <input name='input_2' id='input_6_2' type='text' value='' class='medium' aria-required="true" aria-invalid="false" /> </div></li><li id='field_6_7' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label' for='input_6_7' >Profession / Role<span class='gfield_required'>*</span></label><div class='ginput_container ginput_container_select'><select name='input_7' id='input_6_7' class='medium gfield_select' aria-required="true" aria-invalid="false"><option value='Veterinarian' >Veterinarian</option><option value='Veterinary Nurse / Technician' >Veterinary Nurse / Technician</option><option value='Practice Manager / Veterinary Assistant / Support Staff' >Practice Manager / Veterinary Assistant / Support Staff</option><option value='Student (Veterinarian or Veterinary Nurse)' >Student (Veterinarian or Veterinary Nurse)</option><option value='Other' >Other</option></select></div></li><li id='field_6_20' class='gfield gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below field_description_below gfield_visibility_visible' ><br></li><li id='field_6_15' class='gfield field_sublabel_below field_description_above gfield_visibility_visible' ><label class='gfield_label' >Inbox Preferences</label><div class='gfield_description' id='gfield_description_6_15'>Customize your inbox by selecting the areas you are most interested in. </div><div class='ginput_container ginput_container_checkbox'><ul class='gfield_checkbox' id='input_6_15'><li class='gchoice_6_15_1'> <input name='input_15.1' type='checkbox' value='NAVC Better Care Weekly&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;A weekly roundup of the new and noteworthy innovations and educational opportunities in the veterinary industry.&lt;/div&gt;' checked='checked' id='choice_6_15_1' /> <label for='choice_6_15_1' id='label_6_15_1'>NAVC Better Care Weekly<br><div style="font-size: 12px; color: #808080;">A weekly roundup of the new and noteworthy innovations and educational opportunities in the veterinary industry.</div></label> </li><li class='gchoice_6_15_2'> <input name='input_15.2' type='checkbox' value='Today&#039;s Veterinary Business eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Covers topics relating to practice management, financial metrics, marketing, retailing and merchandising, and industry news.&lt;/div&gt;' id='choice_6_15_2' /> <label for='choice_6_15_2' id='label_6_15_2'>Today's Veterinary Business eNewsletter<br><div style="font-size: 12px; color: #808080;">Covers topics relating to practice management, financial metrics, marketing, retailing and merchandising, and industry news.</div></label> </li><li class='gchoice_6_15_3'> <input name='input_15.3' type='checkbox' value='Today&#039;s Veterinary Nurse eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Provides practical, peer-reviewed companion animal educational CE for veterinary nurses, technicians and assistants.&lt;/div&gt;' id='choice_6_15_3' /> <label for='choice_6_15_3' id='label_6_15_3'>Today's Veterinary Nurse eNewsletter<br><div style="font-size: 12px; color: #808080;">Provides practical, peer-reviewed companion animal educational CE for veterinary nurses, technicians and assistants.</div></label> </li><li class='gchoice_6_15_4'> <input name='input_15.4' type='checkbox' value='Today&#039;s Veterinary Practice eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Provides practical, peer-reviewed articles focused on the latest diagnostic and treatment techniques to enhance your knowledge and confidence.&lt;/div&gt;' id='choice_6_15_4' /> <label for='choice_6_15_4' id='label_6_15_4'>Today's Veterinary Practice eNewsletter<br><div style="font-size: 12px; color: #808080;">Provides practical, peer-reviewed articles focused on the latest diagnostic and treatment techniques to enhance your knowledge and confidence.</div></label> </li><li class='gchoice_6_15_5'> <input name='input_15.5' type='checkbox' value='VetFolio eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Discover online CE resources offered in a variety of formats including videos, podcasts, webinars and more.&lt;/div&gt;' id='choice_6_15_5' /> <label for='choice_6_15_5' id='label_6_15_5'>VetFolio eNewsletter<br><div style="font-size: 12px; color: #808080;">Discover online CE resources offered in a variety of formats including videos, podcasts, webinars and more.</div></label> </li><li class='gchoice_6_15_6'> <input name='input_15.6' type='checkbox' value='Partner Emails&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Exclusive deals and information from our partners.&lt;/div&gt;' id='choice_6_15_6' /> <label for='choice_6_15_6' id='label_6_15_6'>Partner Emails<br><div style="font-size: 12px; color: #808080;">Exclusive deals and information from our partners.</div></label> </li></ul></div></li><li id='field_6_19' class='gfield gfield_html gfield_html_formatted field_sublabel_below field_description_below gfield_visibility_visible' ><br></li><li id='field_6_22' class='gfield field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label' >Do you want to be added to our postal mailing list?</label><div class='ginput_container ginput_container_checkbox'><ul class='gfield_checkbox' id='input_6_22'><li class='gchoice_6_22_1'> <input name='input_22.1' type='checkbox' value='Yes, I love mail!' id='choice_6_22_1' /> <label for='choice_6_22_1' id='label_6_22_1'>Yes, I love mail!</label> </li><li class='gchoice_6_22_2'> <input name='input_22.2' type='checkbox' value='No thank you.' id='choice_6_22_2' /> <label for='choice_6_22_2' id='label_6_22_2'>No thank you.</label> </li></ul></div></li><li id='field_6_10' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label gfield_label_before_complex' >Please provide your mailing address below.<span class='gfield_required'>*</span></label> <div class='ginput_complex ginput_container has_street has_street2 has_city has_state has_zip has_country ginput_container_address' id='input_6_10' > <span class='ginput_full address_line_1' id='input_6_10_1_container' > <input type='text' name='input_10.1' id='input_6_10_1' value='' aria-required="true"/> <label for='input_6_10_1' id='input_6_10_1_label' >Street Address</label> </span><span class='ginput_full address_line_2' id='input_6_10_2_container' > <input type='text' name='input_10.2' id='input_6_10_2' value='' /> <label for='input_6_10_2' id='input_6_10_2_label' >Address Line 2</label> </span><span class='ginput_left address_city' id='input_6_10_3_container' > <input type='text' name='input_10.3' id='input_6_10_3' value='' aria-required="true"/> <label for='input_6_10_3' id='input_6_10_3_label' >City</label> </span><span class='ginput_right address_state' id='input_6_10_4_container' > <input type='text' name='input_10.4' id='input_6_10_4' value='' aria-required="true"/> <label for='input_6_10_4' id='input_6_10_4_label' >State / Province / Region</label> </span><span class='ginput_left address_zip' id='input_6_10_5_container' > <input type='text' name='input_10.5' id='input_6_10_5' value='' aria-required="true"/> <label for='input_6_10_5' id='input_6_10_5_label' >ZIP / Postal Code</label> </span><span class='ginput_right address_country' id='input_6_10_6_container' > <select name='input_10.6' id='input_6_10_6' aria-required="true"><option value='' selected='selected'></option><option value='Afghanistan' >Afghanistan</option><option value='Åland Islands' >Åland Islands</option><option value='Albania' >Albania</option><option value='Algeria' >Algeria</option><option value='American Samoa' >American Samoa</option><option value='Andorra' >Andorra</option><option value='Angola' >Angola</option><option value='Anguilla' >Anguilla</option><option value='Antarctica' >Antarctica</option><option value='Antigua and Barbuda' >Antigua and Barbuda</option><option value='Argentina' >Argentina</option><option value='Armenia' >Armenia</option><option value='Aruba' >Aruba</option><option value='Australia' >Australia</option><option value='Austria' >Austria</option><option value='Azerbaijan' >Azerbaijan</option><option value='Bahamas' >Bahamas</option><option value='Bahrain' >Bahrain</option><option value='Bangladesh' >Bangladesh</option><option value='Barbados' >Barbados</option><option value='Belarus' >Belarus</option><option value='Belgium' >Belgium</option><option value='Belize' >Belize</option><option value='Benin' >Benin</option><option value='Bermuda' >Bermuda</option><option value='Bhutan' >Bhutan</option><option value='Bolivia' >Bolivia</option><option value='Bonaire, Sint Eustatius and Saba' >Bonaire, Sint Eustatius and Saba</option><option value='Bosnia and Herzegovina' >Bosnia and Herzegovina</option><option value='Botswana' >Botswana</option><option value='Bouvet Island' >Bouvet Island</option><option value='Brazil' >Brazil</option><option value='British Indian Ocean Territory' >British Indian Ocean Territory</option><option value='Brunei Darussalam' >Brunei Darussalam</option><option value='Bulgaria' >Bulgaria</option><option value='Burkina Faso' >Burkina Faso</option><option value='Burundi' >Burundi</option><option value='Cambodia' >Cambodia</option><option value='Cameroon' >Cameroon</option><option value='Canada' >Canada</option><option value='Cape Verde' >Cape Verde</option><option value='Cayman Islands' >Cayman Islands</option><option value='Central African Republic' >Central African Republic</option><option value='Chad' >Chad</option><option value='Chile' >Chile</option><option value='China' >China</option><option value='Christmas Island' >Christmas Island</option><option value='Cocos Islands' >Cocos Islands</option><option value='Colombia' >Colombia</option><option value='Comoros' >Comoros</option><option value='Congo, Democratic Republic of the' >Congo, Democratic Republic of the</option><option value='Congo, Republic of the' >Congo, Republic of the</option><option value='Cook Islands' >Cook Islands</option><option value='Costa Rica' >Costa Rica</option><option value='Côte d&#039;Ivoire' >Côte d&#039;Ivoire</option><option value='Croatia' >Croatia</option><option value='Cuba' >Cuba</option><option value='Curaçao' >Curaçao</option><option value='Cyprus' >Cyprus</option><option value='Czech Republic' >Czech Republic</option><option value='Denmark' >Denmark</option><option value='Djibouti' >Djibouti</option><option value='Dominica' >Dominica</option><option value='Dominican Republic' >Dominican Republic</option><option value='Ecuador' >Ecuador</option><option value='Egypt' >Egypt</option><option value='El Salvador' >El Salvador</option><option value='Equatorial Guinea' >Equatorial Guinea</option><option value='Eritrea' >Eritrea</option><option value='Estonia' >Estonia</option><option value='Eswatini (Swaziland)' >Eswatini (Swaziland)</option><option value='Ethiopia' >Ethiopia</option><option value='Falkland Islands' >Falkland Islands</option><option value='Faroe Islands' >Faroe Islands</option><option value='Fiji' >Fiji</option><option value='Finland' >Finland</option><option value='France' >France</option><option value='French Guiana' >French Guiana</option><option value='French Polynesia' >French Polynesia</option><option value='French Southern Territories' >French Southern Territories</option><option value='Gabon' >Gabon</option><option value='Gambia' >Gambia</option><option value='Georgia' >Georgia</option><option value='Germany' >Germany</option><option value='Ghana' >Ghana</option><option value='Gibraltar' >Gibraltar</option><option value='Greece' >Greece</option><option value='Greenland' >Greenland</option><option value='Grenada' >Grenada</option><option value='Guadeloupe' >Guadeloupe</option><option value='Guam' >Guam</option><option value='Guatemala' >Guatemala</option><option value='Guernsey' >Guernsey</option><option value='Guinea' >Guinea</option><option value='Guinea-Bissau' >Guinea-Bissau</option><option value='Guyana' >Guyana</option><option value='Haiti' >Haiti</option><option value='Heard and McDonald Islands' >Heard and McDonald Islands</option><option value='Holy See' >Holy See</option><option value='Honduras' >Honduras</option><option value='Hong Kong' >Hong Kong</option><option value='Hungary' >Hungary</option><option value='Iceland' >Iceland</option><option value='India' >India</option><option value='Indonesia' >Indonesia</option><option value='Iran' >Iran</option><option value='Iraq' >Iraq</option><option value='Ireland' >Ireland</option><option value='Isle of Man' >Isle of Man</option><option value='Israel' >Israel</option><option value='Italy' >Italy</option><option value='Jamaica' >Jamaica</option><option value='Japan' >Japan</option><option value='Jersey' >Jersey</option><option value='Jordan' >Jordan</option><option value='Kazakhstan' >Kazakhstan</option><option value='Kenya' >Kenya</option><option value='Kiribati' >Kiribati</option><option value='Kuwait' >Kuwait</option><option value='Kyrgyzstan' >Kyrgyzstan</option><option value='Lao People&#039;s Democratic Republic' >Lao People&#039;s Democratic Republic</option><option value='Latvia' >Latvia</option><option value='Lebanon' >Lebanon</option><option value='Lesotho' >Lesotho</option><option value='Liberia' >Liberia</option><option value='Libya' >Libya</option><option value='Liechtenstein' >Liechtenstein</option><option value='Lithuania' >Lithuania</option><option value='Luxembourg' >Luxembourg</option><option value='Macau' >Macau</option><option value='Macedonia' >Macedonia</option><option value='Madagascar' >Madagascar</option><option value='Malawi' >Malawi</option><option value='Malaysia' >Malaysia</option><option value='Maldives' >Maldives</option><option value='Mali' >Mali</option><option value='Malta' >Malta</option><option value='Marshall Islands' >Marshall Islands</option><option value='Martinique' >Martinique</option><option value='Mauritania' >Mauritania</option><option value='Mauritius' >Mauritius</option><option value='Mayotte' >Mayotte</option><option value='Mexico' >Mexico</option><option value='Micronesia' >Micronesia</option><option value='Moldova' >Moldova</option><option value='Monaco' >Monaco</option><option value='Mongolia' >Mongolia</option><option value='Montenegro' >Montenegro</option><option value='Montserrat' >Montserrat</option><option value='Morocco' >Morocco</option><option value='Mozambique' >Mozambique</option><option value='Myanmar' >Myanmar</option><option value='Namibia' >Namibia</option><option value='Nauru' >Nauru</option><option value='Nepal' >Nepal</option><option value='Netherlands' >Netherlands</option><option value='New Caledonia' >New Caledonia</option><option value='New Zealand' >New Zealand</option><option value='Nicaragua' >Nicaragua</option><option value='Niger' >Niger</option><option value='Nigeria' >Nigeria</option><option value='Niue' >Niue</option><option value='Norfolk Island' >Norfolk Island</option><option value='North Korea' >North Korea</option><option value='Northern Mariana Islands' >Northern Mariana Islands</option><option value='Norway' >Norway</option><option value='Oman' >Oman</option><option value='Pakistan' >Pakistan</option><option value='Palau' >Palau</option><option value='Palestine, State of' >Palestine, State of</option><option value='Panama' >Panama</option><option value='Papua New Guinea' >Papua New Guinea</option><option value='Paraguay' >Paraguay</option><option value='Peru' >Peru</option><option value='Philippines' >Philippines</option><option value='Pitcairn' >Pitcairn</option><option value='Poland' >Poland</option><option value='Portugal' >Portugal</option><option value='Puerto Rico' >Puerto Rico</option><option value='Qatar' >Qatar</option><option value='Réunion' >Réunion</option><option value='Romania' >Romania</option><option value='Russia' >Russia</option><option value='Rwanda' >Rwanda</option><option value='Saint Barthélemy' >Saint Barthélemy</option><option value='Saint Helena' >Saint Helena</option><option value='Saint Kitts and Nevis' >Saint Kitts and Nevis</option><option value='Saint Lucia' >Saint Lucia</option><option value='Saint Martin' >Saint Martin</option><option value='Saint Pierre and Miquelon' >Saint Pierre and Miquelon</option><option value='Saint Vincent and the Grenadines' >Saint Vincent and the Grenadines</option><option value='Samoa' >Samoa</option><option value='San Marino' >San Marino</option><option value='Sao Tome and Principe' >Sao Tome and Principe</option><option value='Saudi Arabia' >Saudi Arabia</option><option value='Senegal' >Senegal</option><option value='Serbia' >Serbia</option><option value='Seychelles' >Seychelles</option><option value='Sierra Leone' >Sierra Leone</option><option value='Singapore' >Singapore</option><option value='Sint Maarten' >Sint Maarten</option><option value='Slovakia' >Slovakia</option><option value='Slovenia' >Slovenia</option><option value='Solomon Islands' >Solomon Islands</option><option value='Somalia' >Somalia</option><option value='South Africa' >South Africa</option><option value='South Georgia' >South Georgia</option><option value='South Korea' >South Korea</option><option value='South Sudan' >South Sudan</option><option value='Spain' >Spain</option><option value='Sri Lanka' >Sri Lanka</option><option value='Sudan' >Sudan</option><option value='Suriname' >Suriname</option><option value='Svalbard and Jan Mayen Islands' >Svalbard and Jan Mayen Islands</option><option value='Sweden' >Sweden</option><option value='Switzerland' >Switzerland</option><option value='Syria' >Syria</option><option value='Taiwan' >Taiwan</option><option value='Tajikistan' >Tajikistan</option><option value='Tanzania' >Tanzania</option><option value='Thailand' >Thailand</option><option value='Timor-Leste' >Timor-Leste</option><option value='Togo' >Togo</option><option value='Tokelau' >Tokelau</option><option value='Tonga' >Tonga</option><option value='Trinidad and Tobago' >Trinidad and Tobago</option><option value='Tunisia' >Tunisia</option><option value='Turkey' >Turkey</option><option value='Turkmenistan' >Turkmenistan</option><option value='Turks and Caicos Islands' >Turks and Caicos Islands</option><option value='Tuvalu' >Tuvalu</option><option value='Uganda' >Uganda</option><option value='Ukraine' >Ukraine</option><option value='United Arab Emirates' >United Arab Emirates</option><option value='United Kingdom' >United Kingdom</option><option value='United States' >United States</option><option value='Uruguay' >Uruguay</option><option value='US Minor Outlying Islands' >US Minor Outlying Islands</option><option value='Uzbekistan' >Uzbekistan</option><option value='Vanuatu' >Vanuatu</option><option value='Venezuela' >Venezuela</option><option value='Vietnam' >Vietnam</option><option value='Virgin Islands, British' >Virgin Islands, British</option><option value='Virgin Islands, U.S.' >Virgin Islands, U.S.</option><option value='Wallis and Futuna' >Wallis and Futuna</option><option value='Western Sahara' >Western Sahara</option><option value='Yemen' >Yemen</option><option value='Zambia' >Zambia</option><option value='Zimbabwe' >Zimbabwe</option></select> <label for='input_6_10_6' id='input_6_10_6_label' >Country</label> </span> <div class='gf_clear gf_clear_complex'></div> </div></li> </ul></div> <div class='gform_footer top_label'> <input type='submit' id='gform_submit_button_6' class='gform_button button' value='Sign Up' onclick='if(window["gf_submitting_6"]){return false;} window["gf_submitting_6"]=true; ' onkeypress='if( event.keyCode == 13 ){ if(window["gf_submitting_6"]){return false;} window["gf_submitting_6"]=true; jQuery("#gform_6").trigger("submit",[true]); }' /> <input type='hidden' class='gform_hidden' name='is_submit_6' value='1' /> <input type='hidden' class='gform_hidden' name='gform_submit' value='6' /> <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' /> <input type='hidden' class='gform_hidden' name='state_6' value='WyJbXSIsIjNkNTNhNjhlOThlOGY4N2JlZWZiNTRmZDhlZDQ5OWI3Il0=' /> <input type='hidden' class='gform_hidden' name='gform_target_page_number_6' id='gform_target_page_number_6' value='0' /> <input type='hidden' class='gform_hidden' name='gform_source_page_number_6' id='gform_source_page_number_6' value='1' /> <input type='hidden' name='gform_field_values' value='' /> </div> </form> </div><script type='text/javascript'> jQuery(document).bind('gform_post_render', function(event, formId, currentPage){if(formId == 6) {gf_global["number_formats"][6] = {"1":{"price":false,"value":false},"2":{"price":false,"value":false},"7":{"price":false,"value":false},"20":{"price":false,"value":false},"15":{"price":false,"value":false},"19":{"price":false,"value":false},"22":{"price":false,"value":false},"10":{"price":false,"value":false}};if(window['jQuery']){if(!window['gf_form_conditional_logic'])window['gf_form_conditional_logic'] = new Array();window['gf_form_conditional_logic'][6] = { logic: { 10: {"field":{"actionType":"show","logicType":"any","rules":[{"fieldId":"22","operator":"is","value":"Yes, I love mail!"}]},"nextButton":null,"section":null} }, dependents: { 10: [10] }, animation: 1, defaults: {"1":{"1.2":"","1.3":"","1.4":"","1.6":"","1.8":""},"15":["choice_6_15_1"],"10":{"10.1":"","10.2":"","10.3":"","10.4":"","10.5":"","10.6":""}}, fields: {"1":[],"2":[],"7":[],"20":[],"15":[],"19":[],"22":[10],"10":[]} }; if(!window['gf_number_format'])window['gf_number_format'] = 'decimal_dot';jQuery(document).ready(function(){gf_apply_rules(6, [10], true);jQuery('#gform_wrapper_6').show();jQuery(document).trigger('gform_post_conditional_logic', [6, null, true]);} );} gformInitChosenFields('#input_6_7','No results matched');} } );jQuery(document).bind('gform_post_conditional_logic', function(event, formId, fields, isInit){gformInitChosenFields('#input_6_7','No results matched');} );</script><script type='text/javascript'> jQuery(document).ready(function(){jQuery(document).trigger('gform_post_render', [6, 1]) } ); </script>